Stock Analysis
United Therapeutics Corporation (UTHR) Stock Analysis
United Therapeutics Corporation (UTHR) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
United Therapeutics Corporation (UTHR) currently has an AIQ Score of 76/100, indicating a bullish setup. Risk is the strongest factor at 83/100. Momentum is the weakest current factor at 68/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
UTHR at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $591.17 |
| AIQ Score | 76/100 |
| Overall View | Bullish |
| Technical Analysis Consensus | Strong Buy |
| Market Cap | $25.24B |
| P/E Ratio (TTM) | 20.7 |
| Forward P/E | — |
| EPS (Q3 FY2026) | $6.06 |
| Revenue (Q3 FY2026) | $832.5M |
| Dividend Yield (TTM) | 0.00% |
| Beta | 0.42 |
| Volume | 463.51K |
| 52-week range | $455.63-$614.23 |
| RSI 14 | 58.01 |
| 50-Day SMA | $542.60 |
| 200-Day SMA | $537.46 |
| Analyst Price Target | $687.40 |
| Next Earnings | Feb 24, 2027 |
UTHRUnited Therapeutics Corporation
Healthcare / Biotechnology
Leader
Sector Leader
Latest quote
- Momentum68
- Value78
- Quality81
- Risk resilience83
- Sentiment—
UTHR Stock Analysis Summary
United Therapeutics Corporation (UTHR) currently has an AIQ Score of 76/100, indicating a bullish setup. Risk resilience is the strongest factor at 83/100. Momentum is the weakest current factor at 68/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a bullish regime, UTHR has AIQ Score of 76/100 with Risk resilience base of 83/100 and fading Momentum at 68/100. Wait for component alignment before adding exposure.
Healthcare · -0.36% stock move · UTHR classified in Biotechnology.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is UTHR Bullish or Bearish Right Now?
UTHR currently has a bullish overall setup. Risk Resilience is the strongest factor at 83/100, while Momentum is weakest at 68/100. The current evidence suggests a constructive setup.
- - Quality is supportive at 81/100.
- - Momentum is constructive at 68/100.
- - Risk Resilience is supportive at 83/100.
- - Price is +8.95% above its 50-day SMA.
- - Analyst target implies +16.28% upside from the latest quote.
- - No strong bearish evidence is available in the current snapshot.
Current Consensus
UTHR's Technical Analysis Consensus is currently Strong Buy, with 31 buy, 9 neutral, and 6 sell votes. UTHR's 14-day RSI is 58.01, which places the stock in a constructive momentum range. UTHR's beta is 0.42, indicating lower market sensitivity than the broad market.
What Changed in UTHR?
The largest recent change in UTHR is AIQ Score moving up by 0.0 points over the available 7-day comparison window. Risk Resilience remains the strongest visible factor.
What Would Change the UTHR Outlook?
The current bullish outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
UTHR Decision Framework
Public evidence layers, setup checks, and risk context for United Therapeutics Corporation.
United Therapeutics Corporation (UTHR) Stock Analysis
United Therapeutics Corporation has an AIQ Score of 76/100 in a Bullish regime. Risk is strongest at 83/100. Beta is 0.42, below market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | UTHR is in a Bullish AIQ regime with score 76/100. |
| Signal Conflict | The primary conflict is that risk leads at 83/100 while momentum lags at 68/100. |
| Factor Evidence | Momentum 68/100 · Value 78/100 · Quality 81/100 · Risk 83/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Risk is the strongest factor at 83/100.
Momentum is 68/100 and RSI (14) is 58.0.
UTHR is in a Bullish regime at 76/100.
Risk factor is 83/100 with beta 0.42 and annual volatility 35.02%.
Current conflict: risk leads at 83/100 while momentum lags at 68/100.
UTHR Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
UTHR Fundamentals
UTHR valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
UTHR Technical Analysis
UTHR technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
UTHR Stock Catalysts
Track UTHR earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
UTHR Dividend Analysis
UTHR dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
UTHR Financial Data
UTHR revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
UTHR Risk Analysis
UTHR volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
UTHR Stock News
UTHR stock news, market tone, recent headlines, and catalyst context.
UTHR vs Biotechnology Peers
Current peer cohort: UTHR · VCEL · VKTX · VOR · VRDN. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| UTHR Current stock | 76/100 | 78/100 | 68/100 | 83/100 | 0.76 | 35.02% | Current |
| VCEL Vericel Corporation | 77/100 | 65/100 | 90/100 | 64/100 | 0.93 | 45.04% | UTHR vs VCEL |
| VKTX Viking Therapeutics, Inc. | 41/100 | — | 47/100 | 41/100 | -0.15 | 69.18% | UTHR vs VKTX |
| VOR Vor Biopharma Inc. | 66/100 | — | 72/100 | 46/100 | 1.15 | 93.53% | UTHR vs VOR |
| VRDN Viridian Therapeutics, Inc. | 58/100 | 37/100 | 91/100 | 46/100 | 0.43 | 71.98% | UTHR vs VRDN |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
Also for UTHR: historical return with reinvested dividends and stock average calculator for several buys.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts8 recent quarterly periods are available for review.
Checked Nov 16, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Sep 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching UTHR
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for UTHR
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
UTHR Stock FAQ
What is UTHR stock price today?
United Therapeutics Corporation's current stock price is $591.17. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is UTHR bullish or bearish right now?
UTHR's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is UTHR's market cap?
UTHR's market cap is $25.24B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is UTHR's current P/E ratio?
UTHR's current P/E ratio is 20.7 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is UTHR's RSI?
UTHR's 14-day RSI is 58.01 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is UTHR above its 50-day and 200-day moving averages?
UTHR is 8.95% from its 50-day SMA and 9.99% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is UTHR's next earnings date?
UTHR's next earnings date is currently listed as Feb 24, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does UTHR pay a dividend?
UTHR's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.